Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva de Lago

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 24, 2024
Involvement of CB<sub>1</sub> and CB<sub>2</sub> receptors in neuroprotective effects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male miceClaudia Gonzalo-Consuegra, Irene Santos-García, Laura García-Toscano, et al.
Scientific Reports|March 12, 2020
Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatmentLoreto Martínez-González, Carmen Rodríguez-Cueto, Diego Cabezudo, et al.
European Journal of Medicinal Chemistry|November 3, 2020
Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosisElisa Rojas-Prats, Loreto Martinez-Gonzalez, Claudia Gonzalo-Consuegra, et al.
Cell Communication and Signaling : CCS|October 11, 2025
Relevance of a peripheral site of action outside the brain-blood barrier for the beneficial effects of CB<sub>2</sub> receptor activation in experimental ALS in male miceMarta Gómez-Almería, Claudia Gonzalo-Consuegra, Carmen Rodríguez-Cueto, et al.
International Journal of Molecular Sciences|February 10, 2021
Retinal Ganglion Cell Loss and Microglial Activation in a SOD1G93A Mouse Model of Amyotrophic Lateral SclerosisPilar Rojas, Ana I Ramírez, Manuel Cadena, et al.
Molecules (Basel, Switzerland)|December 24, 2021
Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson's Disease and Amyotrophic Lateral SclerosisSonia Burgaz, Concepción García, Claudia Gonzalo-Consuegra, et al.
Neuropharmacology|December 13, 2025
Assessment of the therapeutic effect of IGS2.7, a CK1δ protein kinase inhibitor, in combination with riluzole for the treatment of ALS-associated TDP-43 proteinopathyMarta Gomez-Almeria, Loreto Martinez-Gonzalez, Ana Teresa Matos, et al.
Journal of Medicinal Chemistry|January 3, 2022
TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis TherapyVanesa Nozal, Loreto Martínez-González, Marta Gomez-Almeria, et al.
Chimia|September 2, 2024
Enhancing Drug Discovery and Development through the Integration of Medicinal Chemistry, Chemical Biology, and Academia-Industry Partnerships: Insights from Roche's Endocannabinoid System ProjectsJohannes Aebi, Kenneth Atz, Simon M Ametamey, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|March 24, 2024
Involvement of CB<sub>1</sub> and CB<sub>2</sub> receptors in neuroprotective effects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male miceClaudia Gonzalo-Consuegra, Irene Santos-García, Laura García-Toscano, et al.
Scientific Reports|March 12, 2020
Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatmentLoreto Martínez-González, Carmen Rodríguez-Cueto, Diego Cabezudo, et al.
European Journal of Medicinal Chemistry|November 3, 2020
Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosisElisa Rojas-Prats, Loreto Martinez-Gonzalez, Claudia Gonzalo-Consuegra, et al.
Cell Communication and Signaling : CCS|October 11, 2025
Relevance of a peripheral site of action outside the brain-blood barrier for the beneficial effects of CB<sub>2</sub> receptor activation in experimental ALS in male miceMarta Gómez-Almería, Claudia Gonzalo-Consuegra, Carmen Rodríguez-Cueto, et al.
International Journal of Molecular Sciences|February 10, 2021
Retinal Ganglion Cell Loss and Microglial Activation in a SOD1G93A Mouse Model of Amyotrophic Lateral SclerosisPilar Rojas, Ana I Ramírez, Manuel Cadena, et al.
Molecules (Basel, Switzerland)|December 24, 2021
Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson's Disease and Amyotrophic Lateral SclerosisSonia Burgaz, Concepción García, Claudia Gonzalo-Consuegra, et al.
Neuropharmacology|December 13, 2025
Assessment of the therapeutic effect of IGS2.7, a CK1δ protein kinase inhibitor, in combination with riluzole for the treatment of ALS-associated TDP-43 proteinopathyMarta Gomez-Almeria, Loreto Martinez-Gonzalez, Ana Teresa Matos, et al.
Journal of Medicinal Chemistry|January 3, 2022
TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis TherapyVanesa Nozal, Loreto Martínez-González, Marta Gomez-Almeria, et al.
Chimia|September 2, 2024
Enhancing Drug Discovery and Development through the Integration of Medicinal Chemistry, Chemical Biology, and Academia-Industry Partnerships: Insights from Roche's Endocannabinoid System ProjectsJohannes Aebi, Kenneth Atz, Simon M Ametamey, et al.
Pageof 5